3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Colorectal Neoplasms
127
Colonic Neoplasms
54
Rectal Neoplasms
49
Carcinoma, Hepatocellular
29
Stomach Neoplasms
22
Neoplasm Metastasis
22
Neoplasms
11
Pancreatic Neoplasms
9
Cholangiocarcinoma
8
Adenocarcinoma Of Esophagus
8
Esophageal Neoplasms
7
Liver Neoplasms
6
Biliary Tract Neoplasms
5
Recurrence
4
Ovarian Neoplasms
4
Gastrointestinal Neoplasms
4
Esophageal Squamous Cell Carcinoma
3
Digestive System Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Adenocarcinoma
3
Unresectable Metastatic Colorectal Cancer
2
Peritoneal Neoplasms
2
Neoplastic Cells, Circulating
2
Intestinal Neoplasms
2
Gastrointestinal Diseases
2
Gallbladder Neoplasms
2
Colorectal Cancer Metastatic
2
Cirrhosis, Familial, with Pulmonary Hypertension
2
Squamous Cell Carcinoma of Head and Neck
1
Interventions
lutetium Lu 177 dotatate
34
Everolimus
33
lanreotide
13
gallium Ga 68 dotatate
13
Temozolomide
13
Magnetic Resonance Spectroscopy
13
Nivolumab
12
pembrolizumab
11
Octreotide
11
Capecitabine
11
177Lu-octreotide, DOTA(0)-Tyr(3)-
10
cabozantinib
9
Positron Emission Tomography Computed Tomography
9
3-Iodobenzylguanidine
9
surufatinib
8
Sunitinib
8
Specimen Handling
7
Carboplatin
7
pasireotide
6
amino-acid, glucose, and electrolyte solution
6
90Y-octreotide, DOTA-Tyr(3)-
6
lenvatinib
5
Lutetium-177
5
Ipilimumab
5
Fluorodeoxyglucose F18
5
Etoposide
5
Cisplatin
5
Bevacizumab
5
telotristat ethyl
4
olaparib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neuroendocrine Tumors
×
Folfox protocol
×
Clear all
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled